Abstract

IntroductionTo date, there are insufficient data demonstrating the benefits of preclinically administered Ringer-lactate (RL) for the treatment of hemorrhagic shock following trauma. Recent animal experiments have shown that lactate tends to have toxic effects in severe hemorrhagic shock. This study aimed to compare the effects of RL administered in a rat model of severe hemorrhagic shock (mean arterial blood pressure (MAP): 25 to 30 mmHg) and moderate hemorrhagic shock (MAP: 40 to 45 mmHg).MethodsFour experimental groups of eight male Wistar rats each (moderate shock with Ringer-saline (RS), moderate shock with RL, severe shock with RS, severe shock with RL) were established. After achieving the specified depth of shock, animals were maintained under the shock conditions for 60 minutes. Subsequently, reperfusion with RS or RL was performed for 30 minutes, and the animals were observed for an additional 150 minutes.ResultsAll animals with moderate shock that received RL survived the entire study period, while six animals with moderate shock that received RS died before the end of the experiment. Furthermore, animals with moderate shock that received RL exhibited considerable improvements in their acid-base parameters and reduced organ damage.In contrast, in animals with severe shock, only two of the animals receiving RS survived but all of the animals receiving RL died early, before the end of the study period. Moreover, the severe shock animals that were treated with RL exhibited considerably worsened acid-base and metabolic parameters.ConclusionsThe preclinical use of RL for volume replacement has different effects depending on the severity of hemorrhagic shock. RL exhibits detrimental effects in cases of severe shock, whereas it has pronounced protective effects in cases of moderate shock.

Highlights

  • To date, there are insufficient data demonstrating the benefits of preclinically administered Ringer-lactate (RL) for the treatment of hemorrhagic shock following trauma

  • In addition to the top priority defined by the Advanced Trauma LifeSupport (ATLS®), that is, to “stop the bleeding”, volume replacement is typically performed during the preclinical course of hemorrhagic shock treatment by administering crystalloid solutions to maintain microcirculation [5,6,7,8]

  • The same was true for all animals of the moderate shock/

Read more

Summary

Introduction

There are insufficient data demonstrating the benefits of preclinically administered Ringer-lactate (RL) for the treatment of hemorrhagic shock following trauma. Recent animal experiments have shown that lactate tends to have toxic effects in severe hemorrhagic shock. Except for patient positioning (for example, 30° semi-recumbent position), little preclinical management of severe craniocerebral trauma is possible; this condition is the most common cause of premature mortality. In addition to the top priority defined by the Advanced Trauma LifeSupport (ATLS®), that is, to “stop the bleeding”, volume replacement is typically performed during the preclinical course of hemorrhagic shock treatment by administering crystalloid solutions to maintain microcirculation [5,6,7,8]. In particular, animal experiments, have shown that resuscitation with lactate-containing solutions improves hemodynamic parameters, blood coagulation and survival compared to resuscitation using crystalloid solutions without metabolizable anions [9,10,11]. Lactate-containing solutions may alter plasma lactate concentrations, which are used as a marker of hypoxemia, and solutions containing both L-lactate and D-lactate may induce pulmonary and hepatic apoptosis [12,13,14,15]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call